Disease · MONDO_0005366
Trials283
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 9 more are not shown, since the checks do not confirm them.
1 to 20 of 283
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01329419 | HEPSERA Post Marketing Surveillance | 4,393 | 2011-04-05 | Hepatitis B | ADEFOVIR DIPIVOXIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00142298 | Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies | Phase 3 | 1,869 | 2011-07-25 | Chronic Hepatitis B | TELBIVUDINE | Its record names the disease | ClinicalTrials.gov |
| NCT01855997 | A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue | 1,669 | 2016-04-08 | Hepatitis B, Chronic | PEGINTERFERON ALFA-2A | Its record names the disease | ClinicalTrials.gov | |
| NCT01277601 | Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B | Phase 4 | 751 | 2015-09-09 | Chronic Hepatitis B | PEGINTERFERON ALFA-2A, TENOFOVIR DISOPROXIL FUMARATE | Its record names the disease | ClinicalTrials.gov |
| NCT00536263 | PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327) | Phase 3 | 671 | 2010-12-21 | Hepatitis B, Chronic | PEGINTERFERON ALFA-2B | Its record names the disease | ClinicalTrials.gov |
| NCT00410202 | Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus | Phase 3 | 629 | 2012-07-04 | Hepatitis B, Chronic | ADEFOVIR, ENTECAVIR | Its record names the disease | ClinicalTrials.gov |
| NCT00435825 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB). | Phase 4 | 551 | 2013-06-25 | Hepatitis B, Chronic | PEGINTERFERON ALFA-2A | Its record names the disease | ClinicalTrials.gov |
| NCT00324961 | Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B | Phase 4 | 533 | 2009-10-02 | Chronic Hepatitis B | ADEFOVIR DIPIVOXIL | Its record names the disease | ClinicalTrials.gov |
| NCT01300234 | Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB) | Phase 3 | 512 | 2013-08-16 | Hepatitis B | ADEFOVIR DIPIVOXIL, TENOFOVIR DISOPROXIL FUMARATE | Its record names the disease | ClinicalTrials.gov |
| NCT03982186 | A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection | Phase 2 | 471 | 2024-07-10 | Hepatitis B, Chronic | BERSACAPAVIR | Its record names the disease | ClinicalTrials.gov |
| NCT04449029 | A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) | Phase 2 | 457 | 2023-05-16 | Hepatitis B | BEPIROVIRSEN | Its record names the disease | ClinicalTrials.gov |
| NCT01641926 | A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450) | Phase 3 | 402 | 2017-01-12 | Hepatitis B, Chronic | PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B | Its record names the disease | ClinicalTrials.gov |
| NCT00927082 | A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B | Phase 4 | 383 | 2016-03-09 | Hepatitis B, Chronic | PEGINTERFERON ALFA-2A | Its record names the disease | ClinicalTrials.gov |
| NCT00117676 | A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B | Phase 3 | 382 | 2010-05-19 | Chronic Hepatitis B | ADEFOVIR DIPIVOXIL, TENOFOVIR DISOPROXIL FUMARATE | Its record names the disease | ClinicalTrials.gov |
| NCT04225715 | A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B | Phase 2 | 281 | 2025-09-19 | Hepatitis B, Chronic | PEGINTERFERON ALFA-2A, RUZOTOLIMOD, XALNESIRAN | Its record names the disease | ClinicalTrials.gov |
| NCT00116805 | A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B | Phase 3 | 266 | 2010-05-19 | Chronic Hepatitis B | ADEFOVIR DIPIVOXIL, TENOFOVIR DISOPROXIL FUMARATE | Its record names the disease | ClinicalTrials.gov |
| NCT03361956 | An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection | Phase 2 | 232 | 2022-11-17 | Hepatitis B | BERSACAPAVIR, ENTECAVIR, TENOFOVIR DISOPROXIL FUMARATE | Its record names the disease | ClinicalTrials.gov |
| NCT01369212 | Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B | Phase 3 | 201 | 2022-10-12 | Hepatitis B | PEGINTERFERON ALFA-2A, TENOFOVIR DISOPROXIL FUMARATE | Its record names the disease | ClinicalTrials.gov |
| NCT00940485 | A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B | Phase 4 | 200 | 2016-02-22 | Hepatitis B, Chronic | ENTECAVIR, PEGINTERFERON ALFA-2A | Its record names the disease | ClinicalTrials.gov |
| NCT02224456 | Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis | Phase 4 | 197 | 2022-02-14 | Hepatitis B, Chronic | TENOFOVIR DISOPROXIL FUMARATE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005366/trials